Viromed, Eureka to conduct joint research over antibody cancer drug
Published: 2009-10-14 06:56:00
Updated: 2009-10-14 06:56:00
ViroMed Co., a local biopharmaceutical company, says it has signed a memorandum of understanding with the US based Eureka Therapeutics Inc. to accelerate the development of antibody cancer drugs, such as Swiss Drug Giant Roche’s Herceptin.
The agreement will provide ViroMed with Eureka’s propr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
